Lucid Diagnostics/LUCD

$1.24

-4%
-
1D1W1MYTD1YMAX

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. It is also developing EsoCure, which is an esophageal ablation device to treat dysplastic BE before it can progress to EAC.
Ticker
LUCD
Sector
Healthcare
Trading on
NASDAQ
Industry
Medical Equipment & Supplies
CEO
Lishan Aklog
Employees
74
Headquarters
New york, United States

LUCD Metrics

BasicAdvanced
$55.39M
Market cap
-
P/E ratio
-$1.41
EPS
-
Beta
-
Dividend rate

What the Analysts think about LUCD

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
227.42% upside
High $8.50
Low $2.50
$1.24
Current price
$4.06
Average price target

LUCD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,028.57% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$700K
600%
Net income
$-14.2M
25.66%
Profit margin
-2,028.57%
-82.05%

LUCD Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 24.77%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.23
-$0.40
-$0.27
-$0.34
-
Expected
-$0.38
-$0.35
-$0.32
-$0.27
-$0.25
Surprise
-39.27%
14.72%
-15.89%
24.77%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Lucid Diagnostics stock

Buy or sell Lucid Diagnostics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing